Federal Court Ruling Could Be Set Back for Royal Dutch Shell Stock: Royal Dutch Shell Plc (OTCQB: RYDAF), FUJIFILM Holdings Corp. (OTCPINK: FUJIY), Sanofi (OTCQB: SNYNF), Provectus Pharmaceuticals (OTC: PVCT)


Follow this company

Companies Mentioned

OTC:BB:RYDAF / PK:FUJIY / OTC:BB:SNYNF / OTC:BB:PVCT
01/27/2014 [ACCESSWIRE]

Whether a recent federal court ruling will scrap Royal Dutch Shell Plc (OTCQB: RYDAF) Alaska drilling plans remains to be seen, but the uncertainty it creates could affect the oil company’s share price.

Netherlands – based Royal Dutch Shell Plc was one of the most active stocks on Jan. 24, trading 2,216,383 shares, more than 14 times its three-month average volume of 153,679 shares.

The spike in activity comes on the heels of Jan. 23 news that  the oil company’s plans to drill for oil off the coast of Alaska could be delayed because of a US appeals court opinion that the government acted illegally by opening up nearly 30-million acres of US Arctic waters.

Environmental groups are declaring the ruling made by the 9th Circuit Court of Appeals in the U.S. as a solid win in their attempt to nix new drilling by Shell in the Alaskan wilderness. Shell has not responded to the decision, only saying its lawyers are “reviewing the opinion,” according to published reports. Some industry experts believe it would be premature to count Shell out.

On Jan. 24, RYDAF share price closed at $35.82, down 33 cent from the share price of $35.49 the previous day.

Find out what could be the best investor’s move when it comes to RYDAF by getting the complete report here, or by cutting and pasting the following link in your Web browser:

http://www.sixfigurestockpicks.com

Another very active stock on Jan. 24 was FUJIFILM Holdings Corp. (OTCPINK:FUJIY) with more than 826,426 trading hands, more than 16 times its three-month average volume of 48,602 shares.

FUJIFILM hasn’t issued any news, or government filings, so some speculate the volume could have been generated by current volatile market conditions.

On Jan. 24 FUJIY share price closed at $28.95, down 85 cent from the share price of 29.80 the previous day.

Find out what could be the best investor’s move when it comes to FUJIY by getting the complete report here, or by cutting and pasting the following link in your Web browser:

http://www.sixfigurestockpicks.com

Sanofi (OTCQB: SNYNF) stock lost some ground Jan. 24, closing at 98.18, down $3.47 cents from the share price of 101.65 the previous day.

The Paris-based pharmaceutical and maker of various healthcare products announced less than two weeks ago that one of its wholly-owned subsidiaries, Genzyme, is partnering with Alnylam Pharmaceuticals, Inc. to develop and commercialize treatments for rare genetic diseases. As part of the expanded relationship, Genzyme will invest $700 million to become a major Alnylam shareholder, according to the company’s written statement.

Under the new agreement, Genzyme will have significant rights to Alnylam's portfolio of clinical and pre-clinical stage drug candidates.

“This collaboration is an important building block for our future. It strengthens our pipeline and provides us with the opportunity to meet the needs of patients with rare diseases around the world through our well-established global organization.” Genzyme's President and CEO David Meeker said in a written statement.

Find out what could be the best investor’s move when it comes to RYDAF by getting the complete report here, or by cutting and pasting the following link in your Web browser:

http://www.sixfigurestockpicks.com

Provectus Pharmaceuticals (OTC: PVCT), Inc. stock volume skyrocketed Jan. 24, trading 17,927,132 share, more than eight times its  three-month average volume of 2,300,137.

The development-stage pharmaceutical company is developing medicines for oncology and dermatology applications. Provectus product line includes PV-10, a Phase II study completed drug candidate for metastatic melanoma, a Phase I study completed candidate for breast cancer, and a Phase I protocol expansion candidate for liver metastasis.

In addition it is conducting PH-10, a Phase IIc randomized study initiated drug candidate for the treatment of psoriasis, and Phase II study completed candidate for atopic dermatitis. It also develops PH-10 for the treatment of actinic keratosis and severe acne vulgaris.

Moreover, the company develops over-the-counter pharmaceuticals, including GloveAid, a hand cream with antiperspirant and antibacterial properties; Pure-ific line of products to prevent the spread of germs on skin; and Pure-Stick and Pure N Clear acne products.

On Jan. 24 PVCT share price closed at $2.13, up 26 cent from the share price of $1.87 the previous day.

Find out what could be the best investor’s move when it comes to PVCT by getting the complete report here, or by cutting and pasting the following link in your Web browser:

http://www.sixfigurestockpicks.com

 

ABOUT US:

Sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.

Sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.

Sixfigurestockpicks.com  monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals DailyStockMotion.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the Sixfigurestockpicks.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://
www.sixfigurestockpicks.com

Disclosure

Sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.

COMMENTS

Leave a comment...
 * 

Your Name
 *